Multiple sclerosis in childhood and adolescence. Complex, chronic and differentiated

被引:0
|
作者
Blaschek, A. [1 ,2 ]
Huppke, P. [3 ]
Kuempfel, T. [4 ,5 ]
Mueller-Felber, W. [1 ,2 ]
Rostasy, K. [6 ]
机构
[1] Univ Munich, Zentrum Neuromuskulare Erkrankungen & Neuroimmuno, LMU Zentrum iSPZ Hauner,Padiatr Neurol, Dr von Haunerschen Kinderspital,Kinderklin & Kind, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Abt Padiatr Neurol Entwicklungsneurol & Sozialpad, Dr von Haunersches Kinderspital, Lindwurmstr 4, D-80337 Munich, Germany
[3] Klin Kinder & Jugendmed, Abt Neuropadiatrie, Gottingen, Germany
[4] Klinikum Univ Munchen, Inst Klin Neuroimmunol, Campus Grosshadern, Munich, Germany
[5] Klinikum Univ Munchen, Biomed Ctr Munchen, Campus Grosshadern, Munich, Germany
[6] Univ Witten Herdecke, Neuropadiatrie & Entwicklungsneurol, Vest Kinder & Jugendklin Datteln, Witten, Germany
来源
NERVENARZT | 2017年 / 88卷 / 12期
关键词
Symptom flare up; Methylprednisolone; Plasmapheresis; Magnetic resonance imaging; Encephalomyelitis; Therapy; DEMYELINATING DISORDERS; CNS DEMYELINATION; CHILDREN; ONSET; RISK; NATALIZUMAB; ANTIBODIES; DIAGNOSIS; COHORT; AGE;
D O I
10.1007/s00115-017-0422-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pediatric multiple sclerosis (MS) is one of the most important acquired neurological disorders in childhood and adolescence. A timely recognition, diagnosis and treatment are of utmost importance. This article highlights the current state of knowledge on the etiology, pathogenesis, diagnosis, clinical presentation and treatment in childhood. Although the rate of progression of disability in the early years is slower in younger patients compared to adults, a disease-modifying therapy should be started once MS is diagnosed.
引用
收藏
页码:1377 / 1384
页数:8
相关论文
共 50 条